Interleukin-2 mutants with reduced toxicity
Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildtype form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.
1. An interleukin-2 (IL-2) mutant with reduced vasopermeability activity compared to a wildtype form of the IL-2 mutant, said mutant being Arg38Trp, said mutant also comprising a mutation at one or more of positions outside the permeability enhancing peptide region of IL-2, wherein said permeability enhancing peptide region of IL-2 represents position 22 to 58 of IL-2, wherein said wildtype form of the human IL-2 mutant is human IL-2 and wherein said IL-2 mutant is not linked to an antibody.
2. The IL-2 mutant of claim 1 , wherein said mutant comprises a full-length IL-2 molecule.
3. A method of producing a low toxicity interleukin-2 (IL-2) in a form suitable for administration in vivo, said method, comprising formulating the IL-2 mutant of claim 1 with at least one pharmaceutically acceptable carrier.
4. A human interleukin-2 (IL-2) mutant with reduced vasopermeability activity compared to a wildtype form of the IL-2 mutant, said mutant being Arg38Trp and containing a mutation at one or more of positions outside the permeability enhancing peptide region of IL-2, wherein said permeability enhancing peptide region of IL-2 represents position 22 to 58 of IL-2.
5. The IL-2 mutant of claim 4 , wherein said mutant comprises a full-length IL-2 molecule.
6. A method of producing a low toxicity interleukin-2 (IL-2) in a form suitable for administration in vivo, said method, comprising formulating the IL-2 mutant of claim 4 with at least one pharmaceutically acceptable carrier.
7. Purified human interleukin-2 (IL-2) which has a tryptophan residue in place of an arginine residue at position 38 said IL-2 also comprising a mutation at one or more of positions outside the permeability enhancing peptide region of IL-2, wherein said permeability enhancing peptide region of IL-2 represents position 22 to 58 of IL-2.
8. The IL-2 of claim 7 which comprises 133 amino acids.
9. A method of producing a low toxicity interleukin-2 (IL-2) in a form suitable for administration in vivo, said method, comprising formulating the IL-2 mutant of claim 7 with at least one pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising human interleukin-2 (IL-2) which has a tryptophan residue in place of an arginine residue at position 38 said mutant also comprising a mutation at one or more of positions outside the permeability enhancing peptide region of IL-2, wherein said permeability enhancing peptide region of IL-2 represents position 22 to 58 of IL-2.
11. The composition of claim 10 wherein the IL-2 comprises 133 amino acids.